Maintenance Treatment with Bevacizumab Prolongs Survival in an<i>In vivo</i>Ovarian Cancer Model

Seiji Mabuchi(The University of Osaka), Masahide Ohmichi(Osaka University of Pharmaceutical Sciences), Yoshimichi Tanaka(Osaka Medical and Pharmaceutical University), Masahiro Sakata(The University of Osaka), Tadashi Kimura(Osaka University), Robert A. Burger(Mersana Therapeutics (United States)), Kenichiro Morishige(Fukushima Medical University), Satoshi Tsunetoh(Osaka Medical and Pharmaceutical University), Hiroshi Sasaki(Osaka Medical and Pharmaceutical University), Masanori Kanemura(Osaka Medical and Pharmaceutical University), Akiko Tanabe-Kimura(Osaka Medical and Pharmaceutical University), Yoshito Terai(Osaka Medical and Pharmaceutical University)
Clinical Cancer Research
December 1, 2008
10.1158/1078-0432.ccr-08-0243
Cited by 94

Related Papers

Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
|Journal of Clinical Oncology|2007|880
American Society of Clinical Oncology Position Statement on Obesity and Cancer
|Journal of Clinical Oncology|2014|524
Estrogen Induces the Akt-dependent Activation of Endothelial Nitric-oxide Synthase in Vascular Endothelial Cells
|Journal of Biological Chemistry|2001|387
Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin.
|PubMed|2000|249
Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells
|Molecular Cancer Research|2016|232